

**To:** Prescribing Providers

**From:** AmeriHealth Caritas Louisiana

**Date:** August 3, 2021

**Subject:** AmeriHealth Caritas Louisiana Review Authorization for Aduhelm™ (aducanumab-avwa)

Aduhelm™ (aducanumab-avwa) is a new drug indicated for the treatment of Alzheimer's disease and is administered via intravenous infusion. Aduhelm™ was approved using the FDA's accelerated approval pathway. Under the accelerated approval provisions, the FDA is requiring the drug manufacturer to conduct a new randomized, controlled clinical trial to verify the drug's clinical benefit. Based on the currently available efficacy and safety information for this drug, Louisiana Medicaid has determined that the lack of an authorization process would pose an imminent peril to beneficiaries.

Authorization requests submitted to AmeriHealth Caritas Louisiana will be evaluated on a case-by-case basis based on the attached clinical guidance. The prescriber must submit a prior authorization request and all supporting documentation.